Dr. Elisa Long conducts research on patient-level decision-making under uncertainty, specifically related to breast cancer prevention, treatment and survivorship. Through constructing mathematical models of breast cancer progression, she has examined the cost-effectiveness of universal breast cancer susceptibility gene (BRCA) screening and is currently working on a decision support tool for mutation carriers to optimize prophylactic surgery timing to prevent breast and ovarian cancer. Long is a triple-negative breast cancer survivor, diagnosed in 2014 at age 33, when she also learned that she carries a BRCA1 mutation.
Nohdurft E, Long EF, Spinler S. Was Angelina Jolie Right? Optimizing Cancer Prevention Strategies Among BRCA Mutation Carriers. Decision Analysis. 2017 Sep;14(3). doi.org/10.1287/deca.2017.0352.
Long EF, Ganz PA. Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making. JAMA Oncol. 2015 Dec;1(9):1217-8. doi: 10.1001/jamaoncol.2015.2340.